-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In cooperation with Professor Zhang Xinxin from the National Center for Translational Medicine of Shanghai Jiaotong University, Sinopharm’s China Biologics Yang Xiaoming team has taken the lead in revealing the 12-month rise and fall of new crown antibody levels in patients who have recovered from the new crown virus infection in Wuhan, China.
According to Sinopharm China Biotech, at the beginning of the outbreak of the new crown epidemic in Wuhan in 2020, Xiaoming Yang's team was the first to propose the use of convalescent plasma therapy for recovered patients, which is known as the "ballast stone" of the new crown treatment
The results of a 12-month kinetic study of the COVID-19 antibody response in recovered patients showed that more than 70% of recovered patients with naturally-infected COVID-19 still maintained positive levels of COVID-19 antibodies in their bodies within 12 months after infection; according to the results of 1782 plasma samples The results of the analysis showed that the antibody titer level of patients who recovered from natural infection with the new crown stabilized at the 9th month (antibody titer decreased by about 64% compared with the beginning of the infection), and remained stable for at least 12 months after stabilization.
This shows that once the human body's humoral immunity to the new coronavirus is stimulated, the level of new coronavirus antibodies in the body can be maintained for a long time
Due to the rapid control of the new crown epidemic in China, although there were occasional local cases, a pandemic did not recur; Wuhan City has continuously added 0 cases since March 2020 and lifted the ban on the Lihan Channel on April 8.
Although the global epidemic situation is still severe, it is hopeful that more than 2.
It is reported that the new crown inactivated vaccine developed by Sinopharm China Biologics is produced with a safe inactivation process for the whole virus, and the inactivation process maintains the diversity of virus antigen types
Recently, the new coronavirus variant strain has become the new focus of people's attention, and Yang Xiaoming's team is also actively conducting related research
